Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24189590 | 0.84 | CA12 (0.33) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1305982 | 0.83 | DGAT1 (0.40) | CYP4F2CYP4A11CA12CA2CA14 | |
| SCHEMBL1306326 | 0.83 | CYP4F2 (0.35) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL7184587 | 0.80 | CYP4F2 (0.35) | CYP4F2CYP4A11 | |
| Methylamine SCHEMBL6804391 | 0.79 | CYP4F2 (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL26699654 | 0.78 | CYP4F2 (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL22394850 | 0.77 | MAPK1 (0.31) | CYP4F2CYP4A11CA12CA1CA2 | |
| SCHEMBL2312894 | 0.77 | MAPK1 (0.34) | CYP4F2CYP4A11CA12CA1CA2 | |
| SCHEMBL5080852 | 0.77 | DGAT1 (0.36) | CYP4F2CYP4A11CA12CA1CA2 | |
| SCHEMBL18089204 | 0.76 | MEN1 (0.32) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1712547-B1 | BICYCLOESTER DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-8053465-B2 | Bicycloester derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-7754757-B2 | Bicycloester derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20100093825-A1 | Bicycloester derivative | FUKUDA YASUMICHI | 2010-04-15 | — | — | US | disclosed |
| US-20080146818-A1 | Dipeptidylpeptidase IV (DPP-IV) inhibitory activity; (2S,4S)-1-[[N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)); diabetes | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-06-19 | — | — | US | disclosed |
| EP-1712547-A1 | BICYCLOESTER DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093825-A1 | Bicycloester derivative | DPP4, DPP7, DPP3 | CYP4F2 44/4885CYP4A11 147/4885CA12 1285/4885 |
| US-20080146818-A1 | Dipeptidylpeptidase IV (DPP-IV) inhibitory activity; (2S,4S)-1-[[N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)); diabetes | DPP4, DPP7, DPP3 | CYP4F2 349/4885CYP4A11 694/4885CA12 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.